Remove CMS Remove Medicaid Remove Research
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

CMS 111
article thumbnail

New Tool Helps Predict Stroke Outcome with Higher Accuracy

DAIC

29, 2025 Researchers atOchsner Health, led byHernan Bazan, MD, DFSVS, FACS, have developed a predictive model with a 93% accuracy rate in determining whether urgent carotid-intervention patients will regain functional independence. tim.hodson Thu, 01/30/2025 - 15:31 Jan.

Stroke 52
article thumbnail

Bridging the Gap: Enhancing Stroke Recovery Through Digital Health Solutions

DAIC

In January 2024, the Centers for Medicare and Medicaid Services (CMS) began requiring health care organizations to screen for five social factors: Food insecurity Interpersonal safety Housing insecurity Transportation Utilities The purpose of these screenings is to encourage engagement of community-based organizations with resources to address SDOH.

Stroke 115
article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

The data was presented today by Amish Raval , MD, Director of Clinical Cardiovascular Research and Professor of Medicine at the University of Wisconsin-Madison at the Technology and Heart Failure Therapeutics (THT) 2024 annual meeting. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

article thumbnail

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

DAIC

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by Center for Medicare and Medicaid Services (CMS) for both treatment and control procedures. CAUTION - Limited by United States law to investigational use.

article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

The clinical research results presented for the roll-in cohort from our CardiAMP CMI Trial highlight BioCardia’s continuing efforts to transform the treatment paradigm in refractory angina through the promise of a one-time cost effective minimally invasive autologous cell-based therapy,” said Peter Altman , President and CEO.

article thumbnail

The Evolving Computed Tomography Market

DAIC

Coronary Computed Tomography Angiography Developments At RSNA23, ITN had the opportunity to speak with Bhvita Jani, principal analyst at Signify Research, about advancements and trends in medical imaging, including the development of coronary CTA. Rao, MD, FACR, from Thomas Jefferson University Hospitals.